Sign up
Pharma Capital

Indivior edges higher as it reveals latest Sublocade data

Recovering drug addicts who were treated with higher doses of Sublocade were more likely to remain drug-free for longer than those on the lower dose
man with needle
More than 70,000 people died from overdoses in the US last year

Fresh data has shown that Indivior PLC’s (LON:INDV) Sublocade opioid addiction treatment is more effective at higher doses.

Sublocade is a once-monthly injection that Indivior is trying to big up as the replacement for Suboxone – the company’s star asset which is facing severe competition from generic rivals.

READ: 75% of drug addicts abstinent for a year after Sublocade treatment

Patients who were given 300mg doses remained in treatment longer and had a higher study completion rate than those treated with a 100mg dose.

On average, those on the 300mg dosage also remained abstinent for longer.

Indivior said the findings were consistent with previous reports that injecting heroin addicts may benefit from higher doses of buprenorphine – the main ingredient in Suboxone.

“Indivior is planning additional studies to further characterize the patients for whom a higher maintenance dose of SUBLOCADE may be warranted," said chief scientific officer Christian Heidbreder.

In a separate trial, Indivior found that buprenorphine reduced the extent of respiratory depression in people taking the synthetic opioid fentanyl.

“Based on this study, the potential protective effect of 2 ng/ml and higher buprenorphine plasma concentrations against fentanyl-induced respiratory depression warrants additional investigation,” added Heidbreder.

Indivior shares edged 0.9% higher to 100p on Monday morning.

Register here to be notified of future INDV Company articles
View full INDV profile View Profile
View All

Related Articles

cancer scan
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.